In addition, a double-blind, randomized, placebo-controlled trial on CRS patients treated with a low dose of roxythromycin, demonstrated clinical benefit particularly for CRS patients with low levels of IgE [7]. The gene discussed is IGHE; the disease is congenital rubella syndrome.